
Breakthrough Clinical Trial Reveals Better Treatment for Advanced Classic Hodgkin Lymphoma
Breakthrough Clinical Trial Reveals Better Treatment for Advanced Classic Hodgkin Lymphoma
Details
More Products & Services
People

Kimberly Sweeney
Roswell Park Comprehensive Cancer Center
Vice President of Patient Experience

Sai Yendamuri
Roswell Park Comprehensive Cancer Center
Chief Strategy Officer; SVP of Business Development & Outreach; Chair of Thoracic Surgery

Shashi Lele
Roswell Park Comprehensive Cancer Center
Medical Director, International Patients

Sunita Panesar
Roswell Park Comprehensive Cancer Center
Vice President of Strategy, Business Development & Outreach
Description
HIGHLIGHTS:
- Nivolumab (Opdivo) superior to brentuximab vedotin (Adcetris) in combination
- Clinical trial results expected to change the standard of care
- Study published today in The New England Journal of Medicine
- Nivolumab (Opdivo) superior to brentuximab vedotin (Adcetris) in combination
- Clinical trial results expected to change the standard of care
- Study published today in The New England Journal of Medicine

Share
Recent Chats
Share via email
Future: handle WhatsApp here
Future: handle LinkedIn here
Future: handle Twitter here
SUBMENU HERE
Share via Chat
Copy Link